Study of Pembrolizumab (MK-3475) Plus Docetaxel Versus Placebo Plus Docetaxel in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-921/KEYNOTE-921)
Clinical trial NCT03834506 · COMPLETED
Trial details
- NCT number
- NCT03834506
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2019-05-02
- Primary completion
- 2022-06-20
- Enrollment
- 1030
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.